BIO-KEY INTERNATIONAL INC Files 8-K on Financials
Ticker: BKYI · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1019034
Sentiment: neutral
Topics: financial-condition, results-of-operations
TL;DR
BIO-KEY files 8-K with financial updates, check the numbers.
AI Summary
Bio-key International, Inc. filed an 8-K on November 15, 2024, reporting on its results of operations and financial condition as of November 14, 2024. The filing includes financial statements and exhibits, with the company's principal executive offices located at 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07733.
Why It Matters
This 8-K filing provides an update on Bio-key International's financial performance and condition, which is crucial for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant negative events.
Key Players & Entities
- BIO KEY INTERNATIONAL INC (company) — Registrant
- November 14, 2024 (date) — Date of earliest event reported
- November 15, 2024 (date) — Filing Date
- 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07733 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on November 14, 2024.
What is the official filing date of this 8-K report?
The 8-K report was filed on November 15, 2024.
Where are Bio-key International, Inc.'s principal executive offices located?
The principal executive offices are located at 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07733.
What is the Commission File Number for Bio-key International, Inc.?
The Commission File Number is 001-13463.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-11-15 08:15:13
Filing Documents
- bkyi20241114_8k.htm (8-K) — 31KB
- ex_748606.htm (EX-99.1) — 276KB
- logo.jpg (GRAPHIC) — 11KB
- 0001437749-24-035433.txt ( ) — 475KB
- bkyi-20241114.xsd (EX-101.SCH) — 3KB
- bkyi-20241114_def.xml (EX-101.DEF) — 12KB
- bkyi-20241114_lab.xml (EX-101.LAB) — 15KB
- bkyi-20241114_pre.xml (EX-101.PRE) — 12KB
- bkyi20241114_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. On November 14, 2024 BIO-key International, Inc. (the "Company") issued a press release announcing its financial results for its third quarter 2024. A copy of the press release issued by the Company on November 14, 2024 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Financial Statements, Pro Forma Financial Information and Exhibit
Financial Statements, Pro Forma Financial Information and Exhibit. (d) Exhibits. The following exhibit is furnished herewith: 99.1 Press Release, dated November 14, 2024, issued by the Company. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-KEY INTERNATIONAL, INC. Date: November 15, 2024 By: /s/ Cecilia C. Welch Cecilia C. Welch Chief Financial Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated November 14, 2024 issued by the Company.